China’s Walvax Biotechnology Co., Ltd (SHE: 300142) has entered into another manufacturing cooperation agreement with Indonesia-based PT Etana Biotechnologies (Etana) for PCV and HPV vaccines. This builds on an earlier agreement for Etana to provide local manufacturing of Walvax Bio’s COVID-19 mRNA vaccine in Indonesia. Financial details of the partnership were not disclosed. The collaboration between Etana, Walvax Bio, and Abogen Bio has enabled Indonesia to establish local production capabilities for mRNA vaccines.
Vaccine Profile
Compared with mRNA vaccines already approved in the US and Europe, Walvax Bio’s mRNA vaccine is stable at a temperature of 2-8℃. This stability makes it particularly suitable for distribution and storage in various climates. The vaccine has concluded eight clinical studies in Indonesia, including as a basic immunization and sequential booster. The results of these studies have been published in leading journals such as the Lancet Microbe, Cell, Cell Research, and Nature. In September of this year, the vaccine obtained Emergency Use Authorization (EUA) in Indonesia.
Future Implications
The expanded partnership between Walvax Biotechnology and Etana underscores the commitment to enhancing vaccine production and distribution capabilities in Southeast Asia. By leveraging local manufacturing, the collaboration aims to improve access to essential vaccines, including PCV, HPV, and COVID-19 vaccines, contributing to public health initiatives in the region.-Fineline Info & Tech
